UBS Group’s Boundless Bio BOLD Stock Holding History

UBS Group’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5	Hold	2	–	–	﹤0.01%	10352
2026 Q1	$2	Sell	2 -21	-91%	-$25	﹤0.01%	10377
2025 Q4	$27	Buy	23 +22	+2,200%	+$27	﹤0.01%	10330
2025 Q3	$1	Sell	1 -12	-92%	-$14	﹤0.01%	10273
2025 Q2	$13	Sell	13 -7,557	-100%	-$10K	﹤0.01%	10143
2025 Q1	$11.4K	Sell	7,570 -8,379	-53%	-$17.4K	﹤0.01%	8555
2024 Q4	$46.3K	Buy	15,949 +12,971	+436%	+$37.8K	﹤0.01%	7349
2024 Q3	$10.3K	Buy	2,978 +1,063	+56%	+$3.85K	﹤0.01%	7733
2024 Q2	$7.41K	Buy	+1,915	New	+$18.3K	﹤0.01%	7854

Other funds holding BOLD

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

UBS Group's BOLD Position: Q2 2026 in Review

UBS Group held its Boundless Bio (BOLD) position steady in Q2 2026 at 2 shares worth $5. The position accounts for ﹤0.01% of the portfolio, ranked #10352.

UBS Group first reported a position in BOLD in Q2 2024 and has held it in 9 quarters since. The position peaked at $46.3K in Q4 2024. 40 funds tracked by Wall St. Rank hold BOLD as of Q2 2026.

UBS Group held 2 shares of Boundless Bio worth $5 as of Q2 2026.
UBS Group left its Boundless Bio share count unchanged in Q2 2026.
Boundless Bio made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10352 holding.
UBS Group first reported a position in Boundless Bio in Q2 2024 and has held it in 9 quarters since.
UBS Group's Boundless Bio position peaked at $46.3K in Q4 2024.
40 funds tracked by Wall St. Rank held Boundless Bio as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.